TABLE 4.
Frequency and rationale for early discontinuation of posaconazole prophylaxis among patients who met the National Comprehensive Cancer Network criteria
| Characteristic | No. (%) of courses |
P | ||
|---|---|---|---|---|
| Total (n = 741) | Oral suspension (n = 384) | Tablet (n = 357) | ||
| Discontinuation | 115 (15.5) | 56 (14.6) | 59 (16.5) | 0.47 |
| Rationale | 0.26 | |||
| Elevated liver function tests | 32 (27.8) | 13 (23.2) | 19 (32.2) | |
| Inability to take oral formulation | 24 (20.9) | 10 (17.9) | 14 (23.7) | |
| Cost | 21 (18.3) | 8 (14.3) | 13 (22.0) | |
| Low levels/poor absorption | 10 (8.7) | 6 (10.7) | 4 (6.8) | |
| Tolerabilitya | 10 (8.7) | 6 (10.7) | 4 (6.8) | |
| Drug shortage | 3 (2.6) | 3 (5.4) | 0 (0.0) | |
| Drug interaction | 3 (2.6) | 3 (5.4) | 0 (0.0) | |
| QT prolongation | 2 (1.7) | 1 (1.8) | 1 (1.7) | |
| Unknown | 10 (8.7) | 6 (10.7) | 4 (6.8) | |
a
Tolerability included patient-reported symptoms (e.g., nausea) sufficient to warrant discontinuation.